Related Experiment Video

Updated: Jun 11, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary

Mike S Fenton1, Kenneth M Marion, Andrew K Salem

  • 1Endocrinology and Diabetes Division, Department of Medicine, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.

Thyroid : Official Journal of the American Thyroid Association
|July 16, 2010
PubMed
Abstract

Insights

Sunitinib inhibits papillary thyroid cancer cell proliferation by targeting key signaling pathways. This drug also stimulates sodium-iodide symporter (NIS) gene expression, offering potential therapeutic benefits.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Sunitinib malate is a multitargeted receptor tyrosine kinase inhibitor.
  • Papillary thyroid cancer (PTC) with RET/PTC1 rearrangement is a focus of this study.
  • Investigating sunitinib's effects on signal transduction and iodide-metabolizing proteins in PTC is crucial.

Purpose of the Study:

  • To determine the effects of sunitinib on signal transduction pathways in RET/PTC1 rearranged papillary cancer cells.
  • To investigate sunitinib's impact on the gene expression of iodide-metabolizing proteins.
  • To elucidate the mechanism of sunitinib's action in these specific cancer cells.

Main Methods:

  • Investigated sunitinib's effects on cell growth, signal transduction, and thyroid-specific gene expression in RET/PTC1 PTC cell lines.
  • Utilized Western blot analysis to assess protein phosphorylation in key signaling pathways (RET, STAT3, MAPK pathways).
  • Examined the impact of sunitinib on cell cycle progression and apoptosis.

Main Results:

  • Sunitinib inhibited RET/PTC1 cell proliferation, migration, and altered cell morphology in a dose-dependent manner.
  • Sunitinib blocked RET autophosphorylation and STAT3 activation, and induced G0/G1 cell cycle arrest.
  • Sunitinib inhibited cytoplasmic MEK/ERK and SAPK/JNK pathways, leading to increased sodium-iodide symporter (NIS) gene expression.

Conclusions:

  • Sunitinib targets cytosolic MEK/ERK and SAPK/JNK pathways in RET/PTC1 cells.
  • Blocking these pathways contributes to sunitinib's inhibition of cell proliferation.
  • Sunitinib stimulates NIS gene expression in RET/PTC1 cells, potentially through these targeted pathways.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...